Field of the Invention
The present invention relates to devices for dermatology and more particularly to a hand-held instrument with a working end that carries (i) a negative pressure aspiration system, (ii) a source for delivery of a sterile fluids to the skin; and (iii) a skin interface surface in the working end that has specially shape structure for abrading surface layers of the patient's epidermis as the working end is moved over the patient's skin while at the same time causing rapid penetration of the fluids into the skin for therapeutic purposes.
Description of the Related Art
Dermatologists and plastic surgeons have used various methods for removing superficial skin layers to cause the growth of new skin layers (i.e., commonly described as skin resurfacing techniques) since the early 1900's. Early skin resurfacing treatments used an acid such as phenol to etch away surface layers of a patient's skin that contained damage to thereafter be replaced by new skin. (The term damage when referring to a skin disorder is herein defined as any cutaneous defect, e.g., including but not limited to rhytides, hyperpigmentation, acne scars, solar elastosis, other dyschromias, stria distensae, seborrheic dermatitus).
Following the removal of surface skin layers at a particular depth, no matter the method of skin removal, the body's natural wound-healing response begins to regenerate the epidermis and underlying wounded skin layers. The new skin layer will then cytologically and architecturally resemble a younger and more normal skin. The range of resurfacing treatments can be divided generally into three categories based on the depth of the skin removal and wound: (i) superficial exfoliations or peels extending into the epidermis, (ii) medium-depth resurfacing treatments extending into the papillary dermis, and (iii) deep resurfacing treatments that remove tissue to the depth of the reticular dermis (see
Modern techniques for skin layer removal include: CO.sub.2 laser resurfacing which falls into the category of a deep resurfacing treatment; Erbium laser resurfacing which generally is considered a medium-depth treatment; mechanical dermabrasion using high-speed abrasive wheels which results in a medium-depth or deep resurfacing treatment; and chemical peels which may range from a superficial to a deep resurfacing treatment, depending on the treatment parameters. A recent treatment, generally called micro-dermabrasion, has been developed that uses an air-pressure source to deliver abrasive particles directly against a patient's skin at high-velocities to abrade away skin layers. Such a micro-dermabrasion modality may be likened to sandblasting albeit at velocities that do no cause excess pain and discomfort to the patient. Micro-dermabrasion as currently practiced falls into the category of a superficial resurfacing treatment.
A superficial exfoliation, peel or abrasion removes some or all of the epidermis (see
It is useful to briefly explain the body's mechanism of actually resurfacing skin in response to the removal of a significant depth of dermal layers. Each of the above-listed depths of treatment disrupts the epidermal barrier, or a deeper dermal barrier (papillary or reticular), which initiates varied levels of the body's wound-healing response. A superficial skin layer removal typically causes a limited wound-healing response, including a transient inflammatory response and limited collagen synthesis within the dermis. In a medium-depth or a deep treatment, the initial inflammatory stage leads to hemostasis through an activated coagulation cascade. Chemotactic factors and fibrin lysis products cause neutrophils and monocytes to appear at the site of the wound. The neutrophils sterilize the wound site and the monocytes convert to macrophages and elaborate growth factors which initiate the next phase of the body's wound-healing response involving granular tissue formation. In this phase, fibroblasts generate a new extracellular matrix, particularly in the papillary and reticuilar dermis, which is sustained by angiogenesis and protected anteriorly by the reforming epithelial layer. The new extracellular matrix is largely composed of collagen fibers (particularly Types I and III) which are laid down in compact parallel arrays (see
All of the prevalent types of skin damage (rhytides, solar elastosis effects, hyperpigmentation, acne scars, dyschromias, melasma, stria distensae) manifest common histologic and ultrastructural characteristics, which in particular include disorganized and thinner collagen aggregates, abnormalities in elastic fibers, and abnormal fibroblasts, melanocytes and keratinocytes that disrupt the normal architecture of the dermal layers. It is well recognized that there will be a clinical improvement in the condition and appearance of a patient's skin when a more normal architecture is regenerated by the body's wound-healing response. Of most significance to a clinical improvement is skin is the creation of more dense parallel collagen aggregates with decreased periodicity (spacing between fibrils). The body's wound-healing response is responsible for synthesis of these collagen aggregates. In addition to the body's natural wound healing response, adjunct pharmaceutical treatments that are administered concurrent with, or following, a skin exfoliations can enhance the development of collagen aggregates to provide a more normal dermal architecture in the skin—the result being a more youthful appearing skin.
The deeper skin resurfacing treatments, such as laser ablation, chemical peels and mechanical dermabrasion have drawbacks. The treatments are best used for treatments of a patient's face and may not be suited for treating other portions of a patient's body. For example, laser resurfacing of a patient's neck or decolletage may result in post-treatment pigmentation disorders. All the deep resurfacing treatments are expensive, require anesthetics, and must be performed in a clinical setting. Perhaps, the most significant disadvantage to deep resurfacing treatments relates to the post-treatment recovery period. It may require up to several weeks or even months to fully recover and to allow the skin the form a new epidermal layer. During a period ranging from a few weeks to several weeks after a deep resurfacing treatment, the patient typically must wear heavy make-up to cover redness thus making the treatment acceptable only to women.
The superficial treatment offered by micro-dermabrasion has the advantages of being performed without anesthetics and requiring no extended post-treatment recovery period. However, micro-dermabrasion as currently practices also has several disadvantages. First, a micro-dermabrasion treatment is adapted only for a superficial exfoliation of a patient's epidermis which does not treat many forms of damage to skin. Further, the current micro-dermabrasion devices cause abrasive effects in a focused area of the skin that is very small, for example a few mm.sup.2, since all current devices use a single pin-hole orifice that jets air and abrasives to strike the skin in a highly focused area. Such a focused treatment area is suitable for superficial exfoliations when the working end of the device is passed over the skin in overlapping paths. Further, such focused energy delivery is not well suited for deeper skin removal where repeated passes may be necessary. Still further, current micro-dermabrasion devices are not suited for deeper skin removal due to the pain associated with deep abrasions. Other disadvantages of the current micro-dermabrasion devices relate to the aluminum oxide abrasive particles that are typically used. Aluminum oxide can contaminate the working environment and create a health hazard for operators and patients alike. Inhalation of aluminum oxide particles over time can result in serious respiratory disorders.
1. Type “A” Skin Resurfacing System. Referring to
Of particular interest,
In this preferred embodiment, the working end 20 is of any suitable material, such as a transparent medical grade plastic. The transparency of the working end will assist the operator in localizing treatment in a particular targeted skin treatment area. The overall transverse dimension of the working end 20 of
The invention allows the area (e.g., in mm2) of opening 26 be in any selected shape but preferably is an elongate shape in the center of the working end 25. The open distal end 26 comprises the distal termination of passageway 28 and the proximal end of the passageway in handle 18 is connected to a flexible aspiration tube 33 that extends to a remote collection reservoir 35 intermediate to the actual aspiration source 30. The aspiration source 30 thus is adapted to draw the working end 20 and more particularly the skin interface 25 against the skin treatment site TS to perform the method of the invention as will be described below. The aspiration source or negative (−) pressurization source 30 may be any suitable vacuum source known in the art. Between the aspiration source 30 and remote collection reservoir 35 may be a filter 38 subsystem that is known in the art for collecting aspirated skin detritus and spent crystalline agents CA that are captured in the open distal end of passageway chamber 28. The collection reservoir 35 and filter 38 are preferably of inexpensive plastic and other materials that are disposable.
The aspiration source 30 may be provided with an adjustable valve means 40 for adjusting the pressure level setting to any suitable range. The physician will learn from experience how to balance the pressure level to attain the desired level of suction against the patient's skin. A trigger or switch component 42 is provided as a foot-switch (
The working end 20 also carries means for introducing abrasive crystals into the working end or distalmost end of passageway 28 to allow individual loose crystalline agents CA to thereafter be captured between the skin interface 25 and the patient's skin. In this embodiment, two channels 44a-44b are provided together with flexible tubes 46a-46b to introduce the loose crystalline agents CA into the working end (see
It has been found that by a slight negative pressure environment the open end 26 and passageway 28, the crystalline agent will be caused to dribble into, or be sucked into, the passageway 28 in the working end 20. Thereafter, the movement of the working end 20 in a sideways movement over the skin causes a portion of the crystalline agent CA volume to be captured temporarily in the irregular or corrugated surface structure of the skin interface 25. In this process of moving the skin interface 25 over the targeted treatment site TS, it has been found that the sharp-edged crystalline agents are rolled over and over while being pressed into the surface of the skin and thereby abrade and remove the skin surface in a controllably gentle manner that is below any threshold of significant pain.
After the spent crystals are rolled over and over by the skin interface when moving in a first lateral direction across the skin, and after the working end is then is reversed in directional movement across the skin, a portion of the spent crystals and abraded skin debris necessarily roll into the central opening portion 26 wherein the negative pressure environment captures and aspirates the abraded materials to the remote collection reservoir 35.
To facilitate the process described above, the invention is provided with novel aspects that relate to the irregular or ridged surface structure 32 mentioned above. The entire skin interface 25 may be of any suitable plan form (e.g., round, oval, rectangular etc.) and fall within the scope of the invention. More in particular, the interface 25 defines a 1st outer periphery 25A and a 2nd inner periphery 25B that generally are in apposition to one another and are spaced apart by width W with the inner periphery about the edge of opening 26 (see
In a preferred embodiment shown in
The terms irregular or ridged shape structure 32 as used herein mean that a series of at least one projecting edge portion 62a projects distally as a ridge within the skin interface portion 25. The irregular shape structure 32 further typically carries recessed portions or valley portions 62b that are recessed in the proximal direction intermediate to any plurality of projecting edge portions 62a. These surface configurations for convenience are herein termed the primary shape structure (or ridge and valley elements). The width of the skin interface 25 containing shape structure 32 may be from about 2.0 mm. to 25.0 mm. or more and preferably is from about 3.0 mm. to 10.0 mm. The number of ridges preferably are from about 1 ridge to 25 ridges on each side of the opening 26. The height H of any ridge from the apex of the projecting portion 62a to the depth of the valley portion 62b may be from about 0.25 mm. to about 5.0 mm. and is preferably from about 0.5 mm. to about 2.0 m. It has been found that various ridge height dimensions are optimal depending on the patient's skin type. Further, but optionally, it has been found that secondary shape structure of notches or recessed grooves 66 configured across the primary shape structure of ridge and valley elements may help introduce loose crystals to regions of the skin interface 25 in contact with the skin which is desirable. Such secondary grooves 66 are shown in
While the series of primary ridge and valley elements together the secondary grooves seems to be optimal for the method described below, it should be appreciated that the method also may be performed with a skin interface that has (i) only primary ridge and valley elements; (ii) or only a particular surface roughness that is appropriate for partially capturing loose crystals as will be described below-as long as the skin interface has a minimum width of about 3.0 mm. which was described as a preferred width dimension previously.
2. Practice of the Method of the Invention. Now turning to
Next, the operator moves the skin interface 25 across a treatment site TS which is a path on the patient's skin while still actuating moves the trigger 42 thereby maintaining the negative pressure environment in the passageway 26. The negative pressure environment within the working end causes crystalline particles and entrained in air to be drawn into passageway 28 proximate to the skin surface and into the shape structure 32 of the skin interface 25. The sideways or lateral movement of the skin interface 25 captures a portion of the crystals between the interface and the skin surface, in part by over-rolling them. The continued rolling of the sharp-edged crystals trapped between the instrument and the skin surface 70 causes an abrasion and removal of the skin surface in a controllable manner.
As working end is moved in a reverse direction, the negative pressure environment in the passageway 28 captures and aspirates the spent crystals and skin debris to the remote collection reservoir 35. At the end of a particular lateral movement of the working end, the operator may release the trigger 42 which terminates the crystal agent delivery and further allows the operator to easily lift the working end from the patient's skin. The treated path can be easily seen and the operator then can exfoliate another slightly overlapping or adjacent path by repeating the above steps until surface removal is completed over the targeted treatment area.
3. Type “B” Skin Resurfacing System. Referring to
Referring now to
Specific features of the invention may be shown in some figures and not in others, and this is for convenience only and any feature may be combined with another in accordance with the invention. While the principles of the invention have been made clear in the exemplary embodiments, it will be obvious to those skilled in the art that modifications of the structure, arrangement, proportions, elements, and materials may be utilized in the practice of the invention, and otherwise, which are particularly adapted to specific environments and operative requirements without departing from the principles of the invention. The appended claims are intended to cover and embrace any and all such modifications, with the limits only of the true purview, spirit and scope of the invention.
This application is a continuation of U.S. patent application Ser. No. 13/620,164, filed Sep. 14, 2012, which is a continuation of U.S. patent application Ser. No. 11/739,615, filed Apr. 24, 2007, now U.S. Pat. No. 8,337,513, which is a divisional of U.S. patent application Ser. No. 10/699,747, filed Nov. 3, 2003, now U.S. Pat. No. 7,789,886, which is a continuation of U.S. patent application Ser. No. 09/648,025 filed Aug. 25, 2000, now U.S. Pat. No. 6,641,591, which claims the priority benefit under 35 U.S.C. §119(e) of Provisional U.S. patent application No. 60/150,782, filed Aug. 26, 1999, the entire contents of these applications being hereby incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
2608032 | Garver | Aug 1952 | A |
2631583 | Lavergne | Mar 1953 | A |
2701559 | Cooper | Feb 1955 | A |
2712823 | Kurtin | Jul 1955 | A |
2867214 | Wilson | Jan 1959 | A |
2881763 | Robbins | Apr 1959 | A |
2921585 | Schumann | Jan 1960 | A |
3085573 | Meyer et al. | Apr 1963 | A |
3214869 | Stryker | Nov 1965 | A |
3476112 | Elstein | Nov 1969 | A |
3574239 | Sollerud | Apr 1971 | A |
3715838 | Young et al. | Feb 1973 | A |
3865352 | Nelson et al. | Feb 1975 | A |
3866264 | Engquist | Feb 1975 | A |
3948265 | Al Ani | Apr 1976 | A |
3964212 | Karden | Jun 1976 | A |
3977084 | Sloan | Aug 1976 | A |
4121388 | Wilson | Oct 1978 | A |
4155721 | Fletcher | May 1979 | A |
4170821 | Booth | Oct 1979 | A |
4182329 | Smit et al. | Jan 1980 | A |
4203431 | Abura et al. | May 1980 | A |
4216233 | Stein | Aug 1980 | A |
4299219 | Norris, Jr. | Nov 1981 | A |
4378804 | Cortese | Apr 1983 | A |
4560373 | Sugino et al. | Dec 1985 | A |
4646480 | Williams | Mar 1987 | A |
4646482 | Chitjian | Mar 1987 | A |
4655743 | Hyde | Apr 1987 | A |
4676749 | Mabille | Jun 1987 | A |
4706676 | Peck | Nov 1987 | A |
4754756 | Shelanski | Jul 1988 | A |
4757814 | Wang et al. | Jul 1988 | A |
4764362 | Barchas | Aug 1988 | A |
4795421 | Blasius, Jr. et al. | Jan 1989 | A |
4836192 | Abbate | Jun 1989 | A |
4875287 | Creasy et al. | Oct 1989 | A |
4886078 | Shiffman | Dec 1989 | A |
4887994 | Bedford | Dec 1989 | A |
4900316 | Yamamoto | Feb 1990 | A |
4917086 | Feltovich et al. | Apr 1990 | A |
4925450 | Imonti et al. | May 1990 | A |
4957747 | Stiefel | Sep 1990 | A |
5006004 | Dirksing et al. | Apr 1991 | A |
5006339 | Bargery et al. | Apr 1991 | A |
5012797 | Liang et al. | May 1991 | A |
5035089 | Tillman et al. | Jul 1991 | A |
5037431 | Summers | Aug 1991 | A |
5037432 | Molinari | Aug 1991 | A |
5100412 | Rosso | Mar 1992 | A |
5100424 | Jang | Mar 1992 | A |
5119839 | Rudolph | Jun 1992 | A |
5122153 | Harrel | Jun 1992 | A |
5207234 | Rosso | May 1993 | A |
5222956 | Waldron | Jun 1993 | A |
5242433 | Smith et al. | Sep 1993 | A |
5254109 | Smith et al. | Oct 1993 | A |
5368581 | Smith et al. | Nov 1994 | A |
5391151 | Wilmot | Feb 1995 | A |
5417674 | Smith et al. | May 1995 | A |
5419772 | Teitz et al. | May 1995 | A |
5460620 | Smith et al. | Oct 1995 | A |
5470323 | Smith et al. | Nov 1995 | A |
5484427 | Gibbons | Jan 1996 | A |
5562642 | Smith et al. | Oct 1996 | A |
5611687 | Wagner | Mar 1997 | A |
5612797 | Clarke | Mar 1997 | A |
5674235 | Parisi | Oct 1997 | A |
5676643 | Cann et al. | Oct 1997 | A |
5676648 | Henley | Oct 1997 | A |
5683971 | Rose et al. | Nov 1997 | A |
5697920 | Gibbons | Dec 1997 | A |
5707383 | Bays et al. | Jan 1998 | A |
5713785 | Nishio | Feb 1998 | A |
5735833 | Olson | Apr 1998 | A |
5759185 | Grinberg | Jun 1998 | A |
5779519 | Oliver | Jul 1998 | A |
5800446 | Banuchi | Sep 1998 | A |
5807353 | Schmitz | Sep 1998 | A |
5810842 | Di Fiore et al. | Sep 1998 | A |
5813416 | Rudolph | Sep 1998 | A |
5817050 | Klein | Oct 1998 | A |
5846215 | Zygmont | Dec 1998 | A |
5848998 | Marasco, Jr. | Dec 1998 | A |
5861142 | Schick | Jan 1999 | A |
5873881 | McEwen et al. | Feb 1999 | A |
5879323 | Henley | Mar 1999 | A |
5882201 | Salem | Mar 1999 | A |
5885260 | Mehl, Sr. et al. | Mar 1999 | A |
5908401 | Henley | Jun 1999 | A |
5919152 | Zygmont | Jul 1999 | A |
5954730 | Bernabei | Sep 1999 | A |
5971999 | Naldoni | Oct 1999 | A |
5980555 | Barbut et al. | Nov 1999 | A |
6019749 | Fields et al. | Feb 2000 | A |
6024733 | Eggers et al. | Feb 2000 | A |
6027402 | Oliver | Feb 2000 | A |
6039745 | Di Fiore et al. | Mar 2000 | A |
6042552 | Cornier | Mar 2000 | A |
6080165 | DeJacma | Jun 2000 | A |
6080166 | McEwen et al. | Jun 2000 | A |
6090085 | Mehl, Sr. et al. | Jul 2000 | A |
6120512 | Bernabei | Sep 2000 | A |
6129701 | Cimino | Oct 2000 | A |
6136008 | Becker et al. | Oct 2000 | A |
6139553 | Dotan | Oct 2000 | A |
6139554 | Karkar et al. | Oct 2000 | A |
6142155 | Rudolph | Nov 2000 | A |
6149634 | Bernabei | Nov 2000 | A |
6159226 | Kim | Dec 2000 | A |
6162218 | Elbrecht et al. | Dec 2000 | A |
6162232 | Shadduck | Dec 2000 | A |
6183451 | Mehl, Sr. et al. | Feb 2001 | B1 |
6183483 | Chang | Feb 2001 | B1 |
6193589 | Khalaj | Feb 2001 | B1 |
6231593 | Meserol | May 2001 | B1 |
6235039 | Parkin et al. | May 2001 | B1 |
6238275 | Metcalf et al. | May 2001 | B1 |
6241739 | Waldron | Jun 2001 | B1 |
6264666 | Coleman et al. | Jul 2001 | B1 |
6277128 | Muldner | Aug 2001 | B1 |
6283978 | Cheski et al. | Sep 2001 | B1 |
6299620 | Shadduck | Oct 2001 | B1 |
6306119 | Weber et al. | Oct 2001 | B1 |
6306147 | Bernabei et al. | Oct 2001 | B1 |
6322568 | Bernabei et al. | Nov 2001 | B1 |
6368333 | Bernabei et al. | Apr 2002 | B2 |
6387103 | Shadduck | May 2002 | B2 |
6401289 | Herbert | Jun 2002 | B1 |
6409736 | Bernabei | Jun 2002 | B1 |
6410599 | Johnson | Jun 2002 | B1 |
RE37796 | Henley | Jul 2002 | E |
6414032 | Johnson | Jul 2002 | B1 |
6420431 | Johnson | Jul 2002 | B1 |
6423078 | Bays et al. | Jul 2002 | B1 |
6423750 | Johnson | Jul 2002 | B1 |
6432113 | Parkin et al. | Aug 2002 | B1 |
6432114 | Rosso | Aug 2002 | B1 |
6471712 | Burres | Oct 2002 | B2 |
6477410 | Henley et al. | Nov 2002 | B1 |
6482212 | Bernabei et al. | Nov 2002 | B1 |
6488646 | Zygmont | Dec 2002 | B1 |
6494856 | Zygmont | Dec 2002 | B1 |
6500183 | Waldron | Dec 2002 | B1 |
6503256 | Parkin et al. | Jan 2003 | B2 |
6511486 | Mercier et al. | Jan 2003 | B2 |
6514262 | Di Fiore et al. | Feb 2003 | B1 |
6527783 | Ignon | Mar 2003 | B1 |
6535761 | Bernabei | Mar 2003 | B2 |
6540757 | Hruska et al. | Apr 2003 | B1 |
6562013 | Marasco, Jr. | May 2003 | B1 |
6562050 | Owen | May 2003 | B1 |
6564093 | Ostrow et al. | May 2003 | B1 |
6565535 | Zaias et al. | May 2003 | B2 |
6582442 | Simon et al. | Jun 2003 | B2 |
6589218 | Garcia | Jul 2003 | B2 |
6592595 | Mallett et al. | Jul 2003 | B1 |
6629983 | Ignon | Oct 2003 | B1 |
6641591 | Shadduck | Nov 2003 | B1 |
6645184 | Zelickson et al. | Nov 2003 | B1 |
6652888 | Rhoades | Nov 2003 | B2 |
6673081 | Tavger et al. | Jan 2004 | B1 |
6673082 | Mallett et al. | Jan 2004 | B2 |
6685853 | Angelopoulos et al. | Feb 2004 | B1 |
6687537 | Bernabei | Feb 2004 | B2 |
6695853 | Karasiuk | Feb 2004 | B2 |
6735470 | Henley et al. | May 2004 | B2 |
6743211 | Prausnitz et al. | Jun 2004 | B1 |
6743215 | Bernabei | Jun 2004 | B2 |
6764493 | Weber et al. | Jul 2004 | B1 |
6869611 | Kligman et al. | Mar 2005 | B1 |
6905487 | Zimmerman | Jun 2005 | B2 |
6911031 | Muldner | Jun 2005 | B2 |
6924649 | Knoedgen | Aug 2005 | B2 |
6926681 | Ramey et al. | Aug 2005 | B1 |
6942649 | Ignon et al. | Sep 2005 | B2 |
7001355 | Nunomura et al. | Feb 2006 | B2 |
7004933 | McDaniel | Feb 2006 | B2 |
7044938 | La Bianco et al. | May 2006 | B2 |
7052503 | Bernabei | May 2006 | B2 |
7069073 | Henley et al. | Jun 2006 | B2 |
7070488 | Suissa et al. | Jul 2006 | B2 |
7083580 | Bernabei | Aug 2006 | B2 |
7087063 | Carson et al. | Aug 2006 | B2 |
7094252 | Koop | Aug 2006 | B2 |
7115275 | Clarot et al. | Oct 2006 | B2 |
7135011 | Powers et al. | Nov 2006 | B2 |
7153311 | Chung | Dec 2006 | B2 |
7197359 | Tokudome et al. | Mar 2007 | B1 |
7198623 | Fischer et al. | Apr 2007 | B2 |
7232444 | Chang | Jun 2007 | B2 |
7241208 | Suissa et al. | Jul 2007 | B2 |
7276051 | Henley et al. | Oct 2007 | B1 |
7314326 | Rosenberg | Jan 2008 | B2 |
7316657 | Kleinhenz et al. | Jan 2008 | B2 |
7318828 | Revivo | Jan 2008 | B1 |
7320691 | Pilcher et al. | Jan 2008 | B2 |
7320801 | Kelly | Jan 2008 | B2 |
7354423 | Zelickson et al. | Apr 2008 | B2 |
7364565 | Freeman | Apr 2008 | B2 |
7384405 | Rhoades | Jun 2008 | B2 |
7427273 | Mitsui | Sep 2008 | B2 |
7458944 | Liste et al. | Dec 2008 | B2 |
7476205 | Erdmann | Jan 2009 | B2 |
7477938 | Sun et al. | Jan 2009 | B2 |
7482314 | Grimes et al. | Jan 2009 | B2 |
7489989 | Sukhanov et al. | Feb 2009 | B2 |
7507228 | Sun et al. | Mar 2009 | B2 |
7582067 | Van Acker | Sep 2009 | B2 |
7597900 | Zimmer et al. | Oct 2009 | B2 |
7597901 | Clarot et al. | Oct 2009 | B2 |
7658742 | Karasiuk | Feb 2010 | B2 |
7678120 | Shadduck | Mar 2010 | B2 |
7744582 | Sadowski et al. | Jun 2010 | B2 |
7789886 | Shadduck | Sep 2010 | B2 |
7837695 | Hart et al. | Nov 2010 | B2 |
7901373 | Tavger | Mar 2011 | B2 |
7951156 | Karasiuk | May 2011 | B2 |
8025669 | David et al. | Sep 2011 | B1 |
RE42960 | Waldron | Nov 2011 | E |
8048089 | Ignon et al. | Nov 2011 | B2 |
8066716 | Shadduck | Nov 2011 | B2 |
8088085 | Thiebaut et al. | Jan 2012 | B2 |
8128638 | Karasiuk et al. | Mar 2012 | B2 |
8221437 | Waldron et al. | Jul 2012 | B2 |
8236008 | Boone, III et al. | Aug 2012 | B2 |
8277287 | Hart | Oct 2012 | B2 |
8337513 | Shadduck | Dec 2012 | B2 |
8343116 | Ignon et al. | Jan 2013 | B2 |
8814836 | Ignon et al. | Aug 2014 | B2 |
9056193 | Ignon et al. | Jun 2015 | B2 |
9468464 | Shadduck | Oct 2016 | B2 |
9474886 | Ignon et al. | Oct 2016 | B2 |
9486615 | Ignon et al. | Nov 2016 | B2 |
9498610 | Ignon et al. | Nov 2016 | B2 |
9550052 | Ignon et al. | Jan 2017 | B2 |
9566088 | Ignon et al. | Feb 2017 | B2 |
9642997 | Ignon et al. | May 2017 | B2 |
9662482 | Ignon et al. | May 2017 | B2 |
20010023351 | Eilers | Sep 2001 | A1 |
20010037118 | Shadduck | Nov 2001 | A1 |
20010049511 | Coleman et al. | Dec 2001 | A1 |
20020016601 | Shadduck | Feb 2002 | A1 |
20020041891 | Cheski | Apr 2002 | A1 |
20020058952 | Weber et al. | May 2002 | A1 |
20020107527 | Burres | Aug 2002 | A1 |
20020128663 | Mercier et al. | Sep 2002 | A1 |
20020133110 | Citow | Sep 2002 | A1 |
20020133176 | Parkin et al. | Sep 2002 | A1 |
20020151826 | Ramey et al. | Oct 2002 | A1 |
20020151908 | Mallett, Sr. et al. | Oct 2002 | A1 |
20020188261 | Hruska | Dec 2002 | A1 |
20030012415 | Cossel | Jan 2003 | A1 |
20030018252 | Duchon et al. | Jan 2003 | A1 |
20030060834 | Muldner | Mar 2003 | A1 |
20030093040 | Mikszta et al. | May 2003 | A1 |
20030093089 | Greenberg | May 2003 | A1 |
20030097139 | Karasiuk | May 2003 | A1 |
20030167032 | Ignon | Sep 2003 | A1 |
20030187462 | Chang | Oct 2003 | A1 |
20030208159 | Ignon et al. | Nov 2003 | A1 |
20030212127 | Glassman et al. | Nov 2003 | A1 |
20030212415 | Karasiuk | Nov 2003 | A1 |
20040010222 | Nunomura et al. | Jan 2004 | A1 |
20040010269 | Grimes et al. | Jan 2004 | A1 |
20040015139 | La Bianco | Jan 2004 | A1 |
20040087972 | Mulholland et al. | May 2004 | A1 |
20040092895 | Harmon | May 2004 | A1 |
20040092959 | Bernaz | May 2004 | A1 |
20040097967 | Ignon | May 2004 | A1 |
20040122447 | Harmon et al. | Jun 2004 | A1 |
20040127914 | Chung | Jul 2004 | A1 |
20040143274 | Shadduck | Jul 2004 | A1 |
20040162565 | Carson et al. | Aug 2004 | A1 |
20040166172 | Rosati et al. | Aug 2004 | A1 |
20040219179 | McDaniel | Nov 2004 | A1 |
20040236291 | Zelickson et al. | Nov 2004 | A1 |
20040243149 | Lee, Jr. | Dec 2004 | A1 |
20040254587 | Park | Dec 2004 | A1 |
20040267285 | Chang | Dec 2004 | A1 |
20050037034 | Rhoades | Feb 2005 | A1 |
20050038448 | Chung | Feb 2005 | A1 |
20050059940 | Weber et al. | Mar 2005 | A1 |
20050084509 | Bernstein | Apr 2005 | A1 |
20050148958 | Rucinski | Jul 2005 | A1 |
20050203111 | David | Sep 2005 | A1 |
20050209611 | Greenberg | Sep 2005 | A1 |
20050283176 | Law | Dec 2005 | A1 |
20060002960 | Zoeteweij et al. | Jan 2006 | A1 |
20060116674 | Goble et al. | Jun 2006 | A1 |
20060161178 | Lee | Jul 2006 | A1 |
20060189964 | Anderson | Aug 2006 | A1 |
20060191562 | Nunomura | Aug 2006 | A1 |
20060200099 | La Bianco et al. | Sep 2006 | A1 |
20060200172 | Shadduck | Sep 2006 | A1 |
20060200173 | Shadduck | Sep 2006 | A1 |
20060212029 | Arcusa Villacampa et al. | Sep 2006 | A1 |
20060253125 | Ignon | Nov 2006 | A1 |
20060264893 | Sage, Jr. et al. | Nov 2006 | A1 |
20070005078 | Hart et al. | Jan 2007 | A1 |
20070043382 | Cheney | Feb 2007 | A1 |
20070065515 | Key | Mar 2007 | A1 |
20070088371 | Karasiuk | Apr 2007 | A1 |
20070123808 | Rhoades | May 2007 | A1 |
20070154502 | Hattendorf et al. | Jul 2007 | A1 |
20070156124 | Ignon et al. | Jul 2007 | A1 |
20070178121 | First et al. | Aug 2007 | A1 |
20070198031 | Kellogg | Aug 2007 | A1 |
20070208353 | Shadduck | Sep 2007 | A1 |
20070239173 | Khalaj | Oct 2007 | A1 |
20080027328 | Klopotek et al. | Jan 2008 | A1 |
20080091179 | Durkin et al. | Apr 2008 | A1 |
20080103563 | Powell | May 2008 | A1 |
20080119781 | King | May 2008 | A1 |
20080132914 | Bossard et al. | Jun 2008 | A1 |
20080139974 | Da Silva | Jun 2008 | A1 |
20080154161 | Abbott | Jun 2008 | A1 |
20080193493 | Rhoades | Aug 2008 | A1 |
20080200861 | Shalev et al. | Aug 2008 | A1 |
20080208146 | Brandwein et al. | Aug 2008 | A1 |
20080214987 | Xu | Sep 2008 | A1 |
20080215068 | Hart et al. | Sep 2008 | A1 |
20080221548 | Danenberg et al. | Sep 2008 | A1 |
20080243039 | Rhoades | Oct 2008 | A1 |
20080287864 | Rosenberg | Nov 2008 | A1 |
20080300529 | Reinstein | Dec 2008 | A1 |
20080300552 | Cichocki et al. | Dec 2008 | A1 |
20090048557 | Yeshurun et al. | Feb 2009 | A1 |
20090053390 | Sakou et al. | Feb 2009 | A1 |
20090062815 | Karasiuk et al. | Mar 2009 | A1 |
20090099091 | Hantash | Apr 2009 | A1 |
20090099093 | Hantash | Apr 2009 | A1 |
20090124985 | Hasenoehrl et al. | May 2009 | A1 |
20090138026 | Wu | May 2009 | A1 |
20090177171 | Ignon et al. | Jul 2009 | A1 |
20090192442 | Ignon et al. | Jul 2009 | A1 |
20090222023 | Boone, III et al. | Sep 2009 | A1 |
20100045427 | Boone, III et al. | Feb 2010 | A1 |
20100049177 | Boone, III et al. | Feb 2010 | A1 |
20100049210 | Boone, III et al. | Feb 2010 | A1 |
20100217357 | Da Silva | Aug 2010 | A1 |
20100305495 | Anderson et al. | Dec 2010 | A1 |
20110054490 | Hart | Mar 2011 | A1 |
20110066162 | Cohen | Mar 2011 | A1 |
20110082415 | Ignon et al. | Apr 2011 | A1 |
20120022435 | Ignon et al. | Jan 2012 | A1 |
20120041338 | Chickering, III et al. | Feb 2012 | A1 |
20120136374 | Karasiuk | May 2012 | A1 |
20130018317 | Bobroff et al. | Jan 2013 | A1 |
20130066336 | Boone, III et al. | Mar 2013 | A1 |
20130096577 | Shadduck | Apr 2013 | A1 |
20130102978 | Ignon et al. | Apr 2013 | A1 |
20130144280 | Eckhouse et al. | Jun 2013 | A1 |
20130158547 | David | Jun 2013 | A1 |
20140343481 | Ignon | Nov 2014 | A1 |
20140343574 | Ignon et al. | Nov 2014 | A1 |
20150032047 | Ignon et al. | Jan 2015 | A1 |
20150230824 | Shadduck | Aug 2015 | A1 |
20150230825 | Shadduck | Aug 2015 | A1 |
20150231379 | Ignon et al. | Aug 2015 | A1 |
20150265822 | Ignon et al. | Sep 2015 | A1 |
20150272623 | Ignon et al. | Oct 2015 | A1 |
20150290442 | Ignon et al. | Oct 2015 | A1 |
20160038183 | Ignon et al. | Feb 2016 | A1 |
20160256671 | Ignon et al. | Sep 2016 | A1 |
20170036002 | Ignon et al. | Feb 2017 | A1 |
20170065801 | Ignon et al. | Mar 2017 | A1 |
Number | Date | Country |
---|---|---|
34 21 390 | Dec 1985 | DE |
234 608 | Apr 1986 | DE |
10 2004 015815 | Nov 2005 | DE |
0 258 901 | Sep 1987 | EP |
0 564 392 | Mar 1993 | EP |
2106780 | Mar 2016 | EP |
553 076 | Dec 1956 | IT |
118 49 22 | Mar 1985 | IT |
1993-088552 | Dec 1993 | JP |
09-294747 | Nov 1997 | JP |
2003-534881 | Nov 2003 | JP |
2003-339713 | Dec 2003 | JP |
2004-275721 | Oct 2004 | JP |
2006-503627 | Feb 2006 | JP |
2006-204767 | Oct 2006 | JP |
20-0280320 | Jul 2002 | KR |
WO 9711650 | Mar 1997 | WO |
WO 0015300 | Mar 2000 | WO |
WO 0193931 | Dec 2001 | WO |
WO 03073917 | Sep 2003 | WO |
WO 2004037098 | May 2004 | WO |
WO 2005070313 | Aug 2005 | WO |
WO 2004037098 | Feb 2006 | WO |
WO 2006018731 | Feb 2006 | WO |
WO 2007114904 | Oct 2007 | WO |
WO 2009088884 | Jul 2009 | WO |
WO 2009097451 | Aug 2009 | WO |
WO 2012145667 | Oct 2012 | WO |
Entry |
---|
Ex Parte Reexamination Certificate U.S. Pat. No. 6,241,739 C1, Microdermabrasion Device and Method of Treating the Skin Surface, Inventor Stephen H. Waldron, Dec. 11, 2007, and file history through Aug. 8, 2006. |
File History of Reissue U.S. Appl. No. 11/027,590, filed Dec. 29, 2004 (Reissue of U.S. Pat. No. 6,500,183, issued Dec. 31, 2002). |
File History of Reexamination No. 90/007,683 (Reexamination of U.S. Pat. No. 6,241,739, issued Jun. 5, 2001). |
Cox III et al., Decreased Splatter in Dermabrasion, Arch Facial Plastic Surgery, Jan.-Mar. 2000, vol. 2, pp. 23-26. |
Ditre et al., Effect of a-hydroxy acids on photoaged skin: A pilot clinical, histologic, and ultrastructural study, Journal of American Academy of Dermatology, Feb. 1996, vol. 34, No. 2, Part 1, pp. 187-195. |
Harris et al., Combining Manual Dermasanding with Low Strength Trichloroacetic Acid to Improve Antinically Injured Skin, The Journal of Dermatologic Surgery and Oncology, Jul. 1994, vol. 20, No. 7, pp. 436-442. |
File History of Reexamination No. 90/013,284 filed Jul. 2, 2014 (Reexamination of U.S. Pat. No. 6,241,739, dated Jun. 5, 2001). |
Number | Date | Country | |
---|---|---|---|
20150230825 A1 | Aug 2015 | US |
Number | Date | Country | |
---|---|---|---|
60150782 | Aug 1999 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10699747 | Nov 2003 | US |
Child | 11739615 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13620164 | Sep 2012 | US |
Child | 14702509 | US | |
Parent | 11739615 | Apr 2007 | US |
Child | 13620164 | US | |
Parent | 09648025 | Aug 2000 | US |
Child | 10699747 | US |